Abstract: INTRODUCTION: Antiangiogenic approaches are currently the dominating experimental therapeutic strategy in glioblastoma. First enthusiasm was provoked by promising radiological response rates and an apparent clinical benefit with some of these agents. Major limitations include the modest number of durable responses, the lack of cytotoxic antitumor activity, of synergy when combined with chemotherapy and of an overall survival benefit. AREAS COVERED: We review the rationale as well as preclinical and clinical evidence for the future development of antiangiogenic agents in glioblastoma. The most prominent approach targets VEGF and includes agents such as the VEGF antibody bevacizumab, the VEGF receptor fusion protein aflibercept or the tyrosine kinase inhibitors cediranib and XL-184. Inhibition of angiogenic pathways by small molecules, for example, enzastaurin, or anti-integrin-based approaches, for example, cilengitide, represent alternative strategies. EXPERT OPINION: Enzastaurin and cediranib failed in randomized Phase III trials in recurrent glioblastoma, aflibercept in Phase II. By contrast, bevacizumab was conditionally approved in many countries. Recently completed Phase III trials for bevacizumab and cilengitide in the first-line setting will define the future role of these agents. This intense clinical trial activity reflects the hope that antiangiogenic agents will become part of the limited therapeutic options for glioblastoma. Expert opinion: Enzastaurin and cediranib failed in randomized phase III trials in recurrent glioblastoma, aflibercept in phase II. In contrast, bevacizumab was conditionally approved in many countries. Recently completed phase III trials for bevacizumab and cilengitide in the first-line setting will define the future role of these agents. This intense clinical trial activity reflects the hope that antiangiogenic agents will become part of the limited therapeutic options for glioblastoma.
Introduction
Glioblastoma is the most common and most malignant primary brain tumor in adults. Despite advances in the understanding of genetic and biologic characteristics of this tumor, the prognosis remains poor with a median survival of approximately 10 months in recent population-based studies [1] . Since 2005, the standard of care of newly diagnosed glioblastoma includes surgery or biopsy followed by radiotherapy and concomitant and adjuvant temozolomide [2] . At tumor recurrence, there is no generally accepted salvage therapy. Competing regimens include temozolomide rechallenge commonly using a doseintensified regimen [3] , nitrosoureas [4, 5] or novel antiangiogenic agents. Since glioblastomas are highly vascularized tumors, various agents targeting angiogenesis have been tested in clinical trials. Here, we review the preclinical and clinical data on currently explored antiangiogenic agents and approaches.
Rationales for the use of antiangiogenic agents in glioma
The formation and development of blood vessels represent pivotal steps during embryogenesis. In the adult, physiological angiogenesis is restricted to the maintenance of tissue homeostasis and integrity which is required during wound healing, inflammation and the menstrual cycle [6] . The pioneers of angiogenesis research suggested that a tumor mass cannot exceed a diameter of 0.4 to 1.0 mm without establishing its own vasculature and recruiting a vascular network for further tumor growth [7] . Conceptually, the de novo formation of blood vessels was defined as vasculogenesis which is mediated by the differentiation of precursor cells into endothelial cells whereas angiogenesis represents the development of new vessels from a pre-existing vascular network [8] . In the last decades several milestones have been reached in the understanding of molecular mechanisms involved in this process. 
Identification of key molecules in the process of angiogenesis
Basic and acidic fibroblast growth factor (bFGF/aFGF) which are secreted by various cancer cells were among the first signaling molecules shown to induce angiogenesis by stimulating the proliferation and differentiation of endothelial cells [9] . The 22 members of the FGF family, ranging from 17 to 34 kDa in size and interacting with tyrosine kinase FGF receptors, play an important role in multiple physiologic processes of embryonic development and wound healing, but can also promote pathologic angiogenesis [10] .
With vascular endothelial growth factor (VEGF), a very potent and more specific angiogenic factor was identified, giving further support to the concept that tumors depend on the development of new blood vessels. VEGF-A is the predominant and most angiogenic of the vascular growth factors and exists in different isoforms derived from alternative splicing of an eight exon-bearing pre-mRNA [11] . Beside the proangiogenic isoforms VEGFxxx-a, "xxx" indicating the number of aminoacids (VEGF165a, VEGF189a, VEGF206a), also antiangiogenic isoforms containing a different c-terminal and named VEGFxxx-b have been described [11, 12] .
VEGF-A stimulates proangiogenic signaling via binding to VEGF receptor (VEGFR)-2. The activity of VEGFR-2 can be modulated by the co-receptors and VEGF-binding neuropilins (NRP)-1 and NRP-2. VEGF is also a ligand of VEGFR-1 which may act as an antagonist of angiogenic signaling by trapping VEGF but exhibits simultanously only minor angiogenic signaling due to its weak tyrosine kinase activity [13] . The soluble variant of VEGFR-1 (sVEGFR-1), a truncated about 110 kDa splice variant of the 180 kDa transmembrane receptor VEGFR-1, was also been shown to trap VEGF [14] . VEGFR-1-and sVEGFR-1-related pathways might represent an endogenous control mechanism balancing pro-and antiangiogenic signaling in physiologic conditions and potentially aberrant proangiogenic 5 signaling in pathologic conditions like cancer. Of note, hypoxia which represents a major stimulatory factor of proangiogenic signaling, downregulates the expression of sVEGFR-1 in endothelial cells [15] . Some authors suggest that VEGF-VEGFR-2 signaling may represent an autocrine regulation pathway of glioma cells in addition to the paracrine interplay of tumor and endothelial cells [16, 17] . Further members of the VEGF family represent VEGF-B and placental growth factor (PlGF) which also bind VEGFR-1 and may act as competitive antagonists of VEGF-A. Furthermore PlGF has indirect effects on angiogenesis by stimulating different cell types to upregulate the production of VEGF-A and other angiogenic factors, e.g. FGFs, platelet-derived growth factor (PDGF), stromal cell-derived factor 1 (SDF1), granulocyte colony-stimulating factor (G-CSF) and matrix metalloproteinase (MMP)-9 [18] . PlGF may play an VEGF-independent role in pathologic angiogenesis since PlGF inhibition was shown to inhibit tumor growth by targeting tumor vessels of VEGF(R)-inhibitor resistant tumors [19] . PlGF-related signaling might thus represent an escape pathway mediating resistance to anti-VEGF targeted therapies [18, 20] . However, a pivotal role of PlGF in angiogenesis has also been disputed. Carmeliet and collegues provided evidence for a proangiogenic role in various pathologic conditions, mostly cancer models. Bais and colleagues first refuted any significant effect on tumor angiogenesis in 15 models but later correlated efficacy of anti-PlGF treatment with VEGFR-1 expression in tumor cells [21] [22] [23] .
Beside the VEGF family other pathways and angiogenic factors play a role in the complex process of angiogenesis. Among these, the family of integrins is involved in modulating a pro-or antiangiogenic microenvironment. Integrins are membrane-bound heterodimeric proteins that can be activated by recognizing ligands of the extracellular matrix (ECM), for example laminins or vitronectins. Ligated integrins are involved in the regulation of migration, invasion and survival of endothelial cells, a process that is especially important in 6 conditions of tumor angiogenesis [24] . MMPs interacting with integrin signaling contribute to this crosstalk between endothelial cells, integrins and the ECM by releasing pro-or antiangiogenic factors, i. e. VEGF of FGFs from the ECM via proteolytic cleavage [25] .
After the establishment of vessels a state of quiescence is followed under physiologic conditions. However, this state must be able to switch to angiogenic conditions if required, for example, in case of wound healing. This system of vessel quiescence, stabilization and, if required, destabilization is regulated by the family of angiopoietins (ANG) and its receptors Tie-1 and Tie-2. In absence of Tie-1, Tie-2 can be activated by ANG-1 and ANG-2, leading to an unresponsiveness to angiogenic signals. In presence of Tie-1 a high ratio of ANG-2/ANG-1 results in proangiogenic signaling and vice-versa [26] .
Cellular targets of antiangiogenesis
The first therapeutic concepts of antiangiogenesis have almost exclusively focused on hostderived endothelial cells. They have been considered to be a stable element of the tumor microenvironment and the risk of developing resistance to therapeutic approaches was of minor concern. However, the experience of antiangiogenic therapies in cancer in general and especially in glioblastoma tells that resistance occurs both in a constitutive and an acquired manner. Constitutive resistance which translates into a lack of response to antiangiogenic therapy may be due to multiple proangiogenic pathways acting not only on VEGF signaling, but also involving FGF, PlGF, ANG family members and integrins [13] . The mechanisms of acquired resistance are even less well understood. Different hypotheses have been developed regarding the relationship of endothelial and glioma cells which may at least in part explain the phenomenon of acquired resistance. In 2001, Kunkel and colleagues showed that inhibiting VEGF-driven angiogenesis resulted in a cooption of preexisting cerebral vessels by glioma cells [27] . Another interesting phenomenon, called vasculogenic mimicry, was described by El Hallani and colleagues: glioblastoma stem-like cells adapt endothelial cell- genetic aberrations which are also found in glioma stem-like cells [29] [30] [31] . In addition, the tumor cells developed an endothelial phenotype when cultured under endothelial cell conditions and in a xenograft mouse model, tumor vessels were shown to be of human origin [30] . Of note, VEGF and VEGFR-2 seem to be involved in the transition of "tumor endothelial progenitor cells" into endothelium while the prior step of differentiation of stemlike CD133 + cells is independent of VEGF [29] . Inhibiting VEGF might thus reduce the development of tumor-derived endothelial cells. In contrast, Soda and colleagues suggested that this transdifferentiation pathway is independent of VEGF in vitro and may be even stimulated by inhibiting VEGF in vivo [31] . Further investigation is required to get a better understanding of the complex interplay of glioma and endothelial cells in order to develop suitable strategies inhibiting different forms of angiogenesis.
Putative mechanisms of action of antiangiogenic therapy
The most intuitive goal of a therapeutic approach targeting tumor vessels is to deprive the tumors of blood supply in order to reduce their capability of growth. The underlying mechanism of action would be vascular regression. Another hypothesis represents the concept that antiangiogenic therapy leads to a normalization of a formerly chaotic network of vessels, 8 thus facilitating drug delivery and thereby potentially improving the response to other tumorspecific therapies [32, 33] . Vessel normalization is also likely to reduce an hypoxic tumor environment which is one of the key pathologic factors of glioblastoma and may contribute to radioresistance. Interestingly, hypoxia also facilitates the conditions for so called "gliomainitiating cells" to maintain their stem-like phenotype [34] . In the clinic, antiangiogenic therapy may induce both vascular normalization and regression effects [35] .
Potential side effects and evasion of antiangiogenic therapy
In parallel with the advances in understanding the molecular mechanisms and therapeutic options of tumor angiogenesis serious concerns arose regarding potential side effects of antiangiogenic therapy. Kunkel and colleagues first described an evasive phenotype after anti-VEGFR-targeted therapy in a mouse glioma model which is characterized by an VEGFindependent growth and the cooption of preexisting cerebral vessels [27] . This was supported by several groups reporting an increased invasiveness of tumors after antiangiogenic treatment, both in mice and human glioma and also other cancer models [36, 37] . Whether this concept of an increased local invasiveness triggered by antiangiogenic agents is clinically relevant remains controversial [38, 39] .
Candidate antiangiogenic agents for glioblastoma
Here, we provide an overview about candidate antiangiogenic agents currently tested in phase II and phase III trials of glioblastoma. Figure 1 illustrates the different mechanisms of action of antiangiogenic agents in the interplay of endothelial cells and glioma cells and table 1 gives a short characterization of the different agents including their status in current clinical trials.
Bevacizumab
Preclinical data 9 Bevacizumab, a humanized monoclonal antibody against VEGF (Avastin, Genentech, South San Francisco, CA, and Roche, Basel, Switzerland) is currently the most prominent antiangiogenic agent in the field of glioblastoma. It exhibits six VEGF-targeting residues preventing VEGF from binding to its receptors [40] . First proof of concept regarding indirect anti-tumors effect by targeting VEGF with this antibody was provided in an orthotopic glioma mouse model without affecting glioma cell viability in vitro [41] . More recently, CD133 + stem-like glioma cells were shown to secrete elevated levels of VEGF with a proangiogenic impact both on in vitro angiogenesis models and on in vivo glioma xenograft models that could be suppressed by bevacizumab [42] .
Clinical data
The first larger clinical studies using bevacizumab in patients with malignant glioma were EIAED. The encouraging rates for progression-free survival (PFS) of 46% and the 6-months overall survival rate of 77% paved the way for further bevacizumab-based regimens in clinical trials in glioblastoma [44] . In 2009, Friedman and colleagues published the BRAIN trial which later on served to facilitate the accelerated approval of bevacizumab. In this noncomparative phase II trial, 167 patients with recurrent glioblastoma were randomized to be treated with bevacizumab 10 mg/kg every 2 weeks with or without irinotecan [45] . Accordingly, strictly speaking, this study explored the addition of irinotecan to bevacizumab and not bevacizumab per se. Patients in both arms showed comparative rates for 6-months PFS (42.6% for bevacizumab alone versus 50.3% for the combination) and similar median 10 overall survival (9.2 months for bevacizumab alone versus 8.9 months for the combination).
However, the safety profile of bevacizumab monotherapy was considerably better than in the combination arm (46.4% versus 65.8% grade ≥ 3 adverse events) [45] . In parallel, Kreisl and colleagues conducted a similar phase II trial treating patients with recurrent glioblastoma with 10 mg/kg bevacizumab every two weeks, with an option to add irinotecan at progression. 6-months PFS was 29% and 6-months overall survival rate 57%, with a median overall survival of 31 weeks [46] . No patient showed significant benefit from the addition of irinotecan at progression under bevacizumab. The safety of bevacizumab as a single-agent is generally considered good. The most frequent reported grade 3 and 4 adverse events in the cohorts with bevacizumab monotherapy were arterial or venous thromboembolism (6% and 12.5%), arterial hypertension (8% and 4%), wound healing (2.4% and 0%), bowel perforation (0 and 3%) and proteinuria (0 and 3%) [45, 46] . In contrast to initial expectations, bevacizumab as a single agent does not lead to a major risk of cerebral hemorrhage in glioma patients. Some authors report that the risk may be augmented by concurrent anticoagulation, while others did not observe an increase of bleeding events [47, 48] . The comparison regarding the general risk of cerebral hemorrhage in glioblastoma with or without bevacizumab and/or anticoagulation has not been assessed in a prospective study.
Based on the response rate and presumed clinical benefit reported in the two above-mentioned phase II studies [45, 46] , bevacizumab was conditionally approved in 2009 by the US Food and Drug Administration and subsequently in many other countries for the treatment of recurrent glioblastoma. In contrast, the European Medicines Agency denied the registration of the drug since there was no inclusion of a bevacizumab-free control arm in any trial and therefore no proven effect on overall survival [49] . Further concerns arose regarding the interpretation of the response rates. The response assessment was mainly based on the Macdonald radiographic criteria [45, 46] which may be inappropriate to evaluate antiangiogenic therapies since the reduction in contrast-enhancement may reflect a restoration of the blood-brain barrier only and not signify anti-tumor growth effects [50] . The results from the bevacizumab trials, amongst others, necessitated to include non-contrast-enhancing tumor and thus integration of changes in T2-weighted/FLAIR sequences in the response assessment in the new RANO criteria.
The above-mentioned observations of enhanced infiltration as an escape mechanism from antiangiogenic therapy provoked an ongoing discussion regarding the patterns of progression and failure after bevacizumab. Several authors reported an increased risk of diffuse invasiveness after treatment with bevacizumab in high grade glioma patients [39, [51] [52] [53] . In contrast, there has also been contradictory evidence which suggests no higher incidence of a gliomatosis-like phenotype after treatment with bevacizumab [38, 54] .
The future impact of bevacizumab in the therapy of glioblastoma will depend on the results of two large phase III trials in newly diagnosed glioblastoma which have completed accrual and will provide prospective data comparing bevacizumab-treated and untreated cohorts. Both the registration trial AVAglio (NCT00943826) and the RTOG-0825 trial (NCT00884741) evaluate the addition of bevacizumab to standard temozolomide-based radiochemotherapy in a similar randomized double-blind protocol with reasonable endpoints of overall survival and progression-free survival [55] . In contrast to AVAglio, the RTOG trial did not include patients with a stereotactic biopsy and was conducted in the US where bevacizumab was freely available at recurrence. The implementation of quality of life assessment in these trials will also help to evaluate whether the expected steroid sparing effect translates into improved quality of life. A comparison of patients treated with temozolomide-based radiochemotherapy plus bevacizumab first-line to historical controls indicated a gain in PFS, but not in OS, that was explained by the availability of bevacizumab at recurrence in the US [56] . This may indicate that the RTOG 0825 may miss the OS endpoint, too. On the other hand, this may be different with AVAglio which is conducted in many countries where bevacizumab is not readily available at recurrence. Of note, these considerations all suppose that bevacizumab given at recurrence has an impact on survival. Finally, the data sets will clarify whether bevacizumab alters patterns of relapse when given as first-line treatment.
Interestingly, in contrast to adult glioma patients, a phase II study in pediatric gliomas did not show any objective response which suggests different biologic and angiogenic profiles of pediatric tumors in this respect [57] . Of note, among adult glioma patients, clinical data indicated that bevacizumab shows a better efficacy in elderly patients whose gliomas may be more VEGF-dependent [58].
Aflibercept

Preclinical data
With the rationale to improve anti-VEGF-targeted therapies, the idea to prevent VEGF from interacting with its receptors by administering decoy soluble receptors led to the development of aflibercept (Sanofi-Aventis, Paris, France and Regeneron Pharmaceuticals, Tarrytown, NY). This drug, also called "VEGF trap", is a fusion protein exposing both the domain of VEGFR-1 and VEGFR-2, thereby "trapping" all isoforms of VEGF-A and PlGF [59] .
Aflibercept showed efficacy in several preclinical models of solid tumors [60] [61] [62] . In an orthotopic mouse glioma model aflibercept showed a survival benefit both in initial and advanced phases of tumor development. However, this study also described the development of a VEGF trap-resistant phenotype characterized by progressive tumor growth and increased invasiveness [63] .
Clinical data
Based on the encouraging preclinical data, a single-arm phase II study in recurrent malignant glioma was conducted by the North American Brain Tumor Consortium. 42 patients with 13 recurrent glioblastoma and 16 patients with recurrent anaplastic glioma were treated with 4 mg/kg every two weeks i. v. aflibercept. The results were disappointing in every aspect. The primary endpoint was not met: 6-months PFS was only 7.7% for glioblastoma and 25% for anaplastic glioma patients. In addition, the toxicity of aflibercept, including CNS ischemia and systemic hemorrhage, was considerable and 25% of the patients were removed from the study for toxicity [64] . After this failure in phase II, aflibercept is not expected to play any role in treatment of glioblastoma. However, this may not be generalized to all concepts of cotargeting VEGF and PlGF which currently are under investigation in clinical trials. Since inhibiting VEGF should at least resemble the clinical benefit of bevacizumab and aflibercept is supposed to target VEGF, general doubts arise about the efficacy of the compound.
Cediranib
Preclinical data
Cediranib (AZD2171, Recentin®, AstraZeneca, London, United Kingdom) is an oral ATPcompetitive inhibitor of the tyrosine kinase activity of all VEGF receptors targeting also the PDGF and c-Kit receptors [65] . First proof-of-principle was provided both by targeting in vivo angiogenesis models via inhibiting endochondral ossification or corpora luteal development and by anti-tumor effects in different solid tumor mouse models [66] . In three orthotopic mouse glioma models, cediranib-treated mice exhibited a survival benefit which occurred despite continuous tumor growth and correlated with a potent reduction of tumor edema presumably by vascular normalization effects [67] . Thus, concerns may arise whether the postulated antiangiogenic properties of cediranib translate into reduced tumor growth or simply reflect a reduced vascular permeability.
Clinical data
14
First clinical experience with cediranib derived from a phase I study in advanced solid tumors describing an acceptable toxicity profile up to an oral daily dose of 45 mg [68] . A small phase II study with 16 patients with recurrent glioblastoma, conducted with 45 mg daily, showed a clinically relevant effect on tumor edema and MRI-validated potency to induce vascular normalization [69] . After completion of the trial, a total of 31 patients were analyzed for a primary endpoint of 6-months PFS showing encouraging results of 25.8% and a high radiographic response rate as assessed by Macdonald criteria of 56.7% of patients [70] . Based on these results, a randomized multicenter phase III trial was conducted to compare the efficacy of cediranib alone or in combination with lomustine in recurrent glioblastoma (REGAL; NCT00777153). 325 patients were randomized from 67 centers and ten countries on a 2:2:1 ratio, 131 patients receiving cediranib monotherapy (30 mg daily), 129 patients the combination of cediranib (20 mg daily) and lomustine (110 mg/m 2 every 6 weeks), and 65 patients receiving lomustine and an oral placebo as a control arm [71] . The PFS as primary endpoint was disappointing as there was no statistically significant difference of the cediranib-containing regimens (median PFS of 92 days for cediranib alone and 125 days in combination with lomustine) compared to the median PFS of 82 days of the control group.
The 6-months PFS of 16% for cediranib monotherapy was considerably lower than the 25.8% of the phase II trial. This may be due to a lower dose of cediranib in the phase III trial or patient selection. However, the toxicity of 45 mg/day as administered in the phase II trial was considerable with 12.9% grade 3/4 toxicities, mainly hypertension, diarrhea and fatigue and high percentage (48.4%) of patients requiring drug interruption for toxicity. Nevertheless, another prospective randomized trial assessing the efficacy of cediranib has started enrollment, conducted by the Radiation Oncology Therapy Group (NCT01062425), to explore the addition of cediranib to standard temozolomide-based radiochemotherapy in newly diagnosed glioblastoma. 
Cabozantinib (XL-184)
Preclinical data
Cabozantinib (XL184, Exelixis®, San Francisco, CA) is a dual tyrosine kinase inhibitor targeting the receptors MET and VEGFR-2. The MET ligand HGF also binds NRP-1 and thus may be related to VEGFR-2 proangiogenic signaling [72] . However, HGF-MET signaling is also involved in processes of migration and invasion in glioma and thus represents a promising therapeutic target [73] . In a mouse glioma model the proliferation of tumor and endothelial cells was reduced, resulting in a dose-dependent inhibition of tumor growth [74] .
Interestingly, this effect was not associated with an increased metastatic spread in this model of lung cancer which has been observed in other approaches targeting VEGF-related pathways.
Clinical data
Cabozantinib is currently tested in a phase I dose finding study for newly diagnosed glioblastoma in combination with the standard therapy and has completed accrual for a phase II clinical trial in patients with progressive or recurrent glioblastoma (NCT00704288).
First results of an interim analysis were presented for 124 patients at ASCO 2010. The study was conducted in two cohorts, receiving 125 mg/day or 175 mg/day respectively. The cohort with 175 mg/day was reported to have a 6-months PFS of 21 % and an overall response rate of 21% in patients without and 8% in patients with prior antiangiogenic therapy. At that time, the 6-months PFS for the 125 mg cohort was not yet available. However, the overall response rate of the patients without prior antiangiogenic therapy was reported to be 32 %. Further evaluation of the risk and benefit is warranted after more follow-up data are available [75] .
Regarding the toxicity profile the currently only available information from this trial is that 16 125 mg were better tolerated. A previous report of a phase II study in thyroid cancer reported a considerable toxicity profile including diarrhea, fatigue, palmar plantar erythrodysesthesia, nausea, thromboembolism, mucositis and elevation of liver enzymes [76] .
Enzastaurin
Preclinical data
Enzastaurin HCl (LY317615, Eli Lilly and Company, Indianapolis, Indiana) is an acyclic bisindolylmaleimide, acting as a ATP-competitive inhibitor of protein kinase C-β (PKC-β)
[77]. PKC-β is involved in the downstream signaling of VEGF [78] . The compound showed an inhibitory effect on plasma VEGF levels in small lung cancer and renal cell carcinoma mouse tumor models suggesting antiangiogenic activity [79] . In human glioblastoma orthotopic mouse models Enzastaurin suppressed tumor growth by inducing apoptosis in tumor cells and prolonged survival in synergy with irradiation [80, 81] .
Clinical data
A phase I/II trial was conducted in recurrent glioma with an accrual of 118 patients [82] . In the phase I cohorts three dose levels (525 mg, 700 mg, 900 mg) were explored in patients receiving EIAED. Therapy was mostly well tolerated and the serum levels of patients on EIAED were approximately 80% lower than in those not on EIAED. The most common grade 3/4 adverse events included thrombosis, thrombocytopenia, hemorrhage and elevated alanine aminotransferase levels. In the phase II cohorts, patients not receiving EIAED were treated with 500 or 525 mg/day. The radiographic response rates of 84 evaluable patients were at 25%. Unfortunately this initial response did not translate into a considerable effect on disease control as the 6-months PFS was only 7% for patients with glioblastoma and 16% for patients with anaplastic glioma. Despite these modest results a phase III trial for patients with recurrent glioblastoma was started comparing 500 mg enzastaurin/day with lomustine (100 to 130 mg/m 2 every 6 weeks) [5] . The enrolment was stopped after 266 of 397 initially planned patients since an interim analysis of PFS and OS did not show any significant difference between the treatment with lomustine. Median PFS for enzastaurin was at 1.5 months versus 1.6 months for lomustine and overall survival at 6.1 versus 7.1 months, respectively. In line with these disappointing results, a phase II study in patients with newly diagnosed glioblastoma exploring the addition of enzastaurin at 250 mg/day to standard temozolomide radiochemotherapy did not provide evidence for further benefit [83] .
Cilengitide
Preclinical data
Cilengitide® (Merck KgaA, Darmstadt, Germany) is a synthetic Arginine-GlycineAsparagine< (RGD) pentapeptide binding to the RGD ligand binding site on the integrin receptors αvβ3 and αvβ5 [84] . This interferes with the communication of integrins with their ligands in the extracellular matrix resulting in an impaired signaling to the cell. Inhibiting αvβ3 and αvβ5 integrins counteracts VEGF-or FGF-induced endothelial cell invasion and differentiation which suggests antiangiogenic activity for cilengitide [85] . Interestingly, tumor growth in orthotopic mouse models of glioblastoma and medulloblastoma was inhibited by cilengitide, but unaffected in case of subcutaneous implantation [86] . The effect of cilengitide thus may be highly context-dependent and cilengitide might modulate the tumor microenvironment towards a less permissive angiogenic phenotype. In vitro, cilengitide had no significant effect on tumor cell survival or proliferation and did not alter the sensitivity to temozolomide or irradiation [87] . However, in vivo, combining cilengitide with radiotherapy led to a survival benefit in an orthotopic mouse model compared with either modality alone [88] . 18 
Clinical data
The clinical experience in phase I clinical studies demonstrated a favorable safety profile without determination of maximum tolerated dose or dose limiting toxicity up to 2400 mg, administered intravenously twice weekly [89, 90] . A randomized phase II trial of 81 patients with recurrent glioblastoma comparing 500 mg versus 2000 mg cilengitide twice weekly as a monotherapy confirmed the excellent tolerability. A trend for a better activity was observed at the higher dose of 2000 mg cilengitide with a 6-months PFS of 15% and a median OS of 9.9 months [91] . However, the activity of cilengitide as a single agent was not considered to be sufficient and preclinical data suggested synergistic effects when combining it with irradiation [88] . The combination of cilengitide at 500 mg with standard radiation and temozolomide therapy in 52 patients with newly diagnosed glioblastoma was assessed in a phase II clinical trial. The results were encouraging with a 6-months PFS of 69%, a median overall survival of Preferentially these patients appeared to show the best benefit from the addition of cilengitide to the standard of care. The currently most favored hypothesis for this benefit represents the idea of a vascular normalization effect leading to an improved delivery of temozolomide to the tumor cells. Another phase II trial of cilengitide in newly diagnosed glioblastoma randomized patients to 500 mg versus 2000 mg cilengitide in addition to standard radiochemotherapy. Data of an interim analysis were presented at ASCO 2009, indicating an estimated median survival time of 18.9 months and overall survival at 12 months for all patients of 79.5% [92] . The design of subsequent phase III trials has been based on the observation of a pronounced benefit for patients bearing the MGMT promotor methylation [93] . As the first international multicenter clinical trial the CENTRIC trial incorporated the screening for a molecular marker in the eligibility criteria [94] . Patients with verified methylated MGMT promotor were randomized either to the experimental arm receiving 2000 mg cilengitide in addition to standard radiochemotherapy or to the control arm receiving standard therapy alone. After completion of radiochemotherapy maintainance of cilengitide was intended to be given for up to 18 months. For patients with an unmethylated MGMT promotor a phase II trial, the CORE trial, compares the addition of 2000 mg cilengitide twice weekly (Arm 1) or five times a week (Arm 2) during radiotherapy, followed by cilengitide maintenance, to standard temozolomide radiochemotherapy alone (NCT00813943).
Other agents
A detailed characterization of all approaches targeting angiogenesis in glioblastoma would be beyond the scope of this review. Briefly, we here summarize some other concepts: Chemotherapy in a metronomic, i. e. continuous schedule, is postulated to have an antiangiogenic effect by targeting proliferating endothelial cells [95] . In recurrent glioblastoma, the activity reported for a temozolomide rechallenge with a continuous doseintensified regimen might, at least in part, be explained by an effect on tumor angiogenesis [3] . There is also a broad range of small molecules aiming at inhibiting angiogenic pathways which were evaluated in phase I/II glioblastoma trials. Among these, the tyrosine kinase inhibitors sorafenib and sunitinib so far failed to show relevant activity in recurrent glioblastoma, but were associated with considerable toxicity [96, 97] . Temsirolimus (Torisel®, Wyeth Pharmaceuticals, Madison, NJ), currently under investigation in phase II glioblastoma trials (NCT01019434), is an inhibitor of the phosphoinositide 3-kinase/ mammalian target of rapamycin (mTOR) signaling pathway which can be overexpressed in glioblastomas and is involved in cell cycle regulation. Based on the experiences in renal cell carcinoma an antiangiogenic effect of the drug is postulated [98] . Vascular disruption is a 20 novel concept aiming at completely compromising the established structure of the tumor vasculature. In glioblastoma, first experience has been published for the α-tubulin antagonist CYT997 which showed vascular disrupting efficacy in preclinical models and in 3 of 6 evaluable patients in an ongoing phase I study in recurrent glioblastoma [99] . Cerebrovascular toxicity was within dose-limiting adverse events and will be of concern in the future development of this concept.
Conclusion
A growing understanding of key mechanisms of angiogenesis led to the development of various antiangiogenic agents with activity in preclinical glioma models. However, these findings did not always translate into progression or survival benefit in clinical trials. Several agents failed to prove efficacy in phase II and phase III trials. The monoclonal antibody against VEGF, bevacizumab, was approved as the first antiangiogenic drug in the treatment of (recurrent) glioblastoma mainly because of its activity on progression-free survival and a presumed clinical benefit. Currently conducted phase III trials for bevacizumab and cilengitide will define the future role of these two candidate antiangiogenic agents in glioblastoma. Third, antiangiogenic agents alone are unlikely to be very effective. However, for bevacizumab, so far no clinical trial in glioblastoma showed superiority of a combined regimen compared to bevacizumab alone. The addition of cytotoxic agents e.g. irinotecan or carboplatin, but also small molecules like erlotinib did not show additional benefit but mostly was associated with an unfavorable safety profile [46, 100, 101] . The lack of efficacy may be due to the fact that some of the cytotoxic agents that have been applied simply do not have activity on glioma cells and thus an increased availability of the drug does not improve their efficacy. Second, the effect of vascular normalization may not only affect the intratumoral vessels but may also restore a formerly impaired blood-brain barrier which could lead to a reduced bioavailability of the drugs. However, the combination of different antiangiogenic 22 agents might be a promising approach based on the current understanding of VEGFdependent and VEGF-independent angiogenic signaling. Despite the failure of aflibercept, cotargeting VEGF and PlGF remains a potential concept to overcome resistance to antiangiogenic therapies. A very promising combination partner of bevacizumab but also other antiangiogenic agents represents radiotherapy. Since vascular normalization may result in an improved oxygenation of the tissue, this is likely to increase the effect of ionizing radiation. Preclinical evidence for this concept comes from a mouse glioma model [102] . A recent phase II study of 25 patients with recurrent glioma treated with hypofractionated radiotherapy plus bevacizumab reported a 6-months PFS of 65%, suggesting activity of this concept [103] .
Expert opinion
Fourth, clinical trials should have a design which enables valid conclusions implicating reasonable endpoints, an appropriate response assessment tailored for the evaluation of antiangiogenic therapies and the use of verum-free control arms, that is without the investigative agent. [50] . The future design of clinical trials in glioblastoma will depend on the outcome of the two large randomized trials for primary diagnosed glioblastoma. The approval of either cilengitide or bevacizumab in the first-line setting would strongly affect the future design of clinical trials in glioblastoma.
In conclusion, the intense clinical trial activity reflects the current hope that antiangiogenic agents will become part of the still very limited therapeutic options for glioblastoma. no specific toxicities known [89, 90] Abbreviations: ATP (Adenosine triphosphate), PlGF (Placental growth factor), PDGFR (Platelet-derived growth factor receptor), RGD (Arginine-Glycine-Asparagine), VEGF (Vascular endothelial growth factor), VEGFR (VEGF receptor)
